AptamiR Therapeutics
Austin · Founded 2012
About AptamiR Therapeutics
AptamiR Therapeutics is a biotechnology company that focuses on developing a revolutionary treatment for human obesity. Based on an innovative strategy targeting subcutaneous fat cells rather than the central nervous system or the intestinal absorption of food, AptamiR is developing microRNA-targeted therapeutics that enhance thermogenesis, turning fat-storing white adipocytes into fat-burning adipocytes (brown-like, brite or beige). MicroRNAs are attractive drug candidates for complex diseases like obesity, as they can modulate the expression of gene networks. AptamiR is also developing drug delivery approaches that can specifically target microRNA modulators to adipose tissue. It provides treatment for human obesity by targeting peripheral white and brown adipose tissues and is based on an innovative strategy targeting subcutaneous fat cells rather than the central nervous system or the intestinal absorption of food that enables patients to get the excess fat removed from their body. AptamiR Therapeutics was established in 2012 and is headquartered in Austin, Texas.
Company Facts
- Founded: 2012
- Legal name: AptamiR Therapeutics Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $3.0M
- Last round: Series Unknown (Sep 2015)
- Website: aptamir.com
- Phone: 12128368433
Social Profiles
Canonical: https://fsome.com/organization/aptamir-therapeutics-8429729 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.